Hong Sun

发表

Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention

Hong Sun, Q. Qu, Zhenfan Chen, 2016, Front. Pharmacol..

Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.

C. Lines, M. Kryger, J. Wagner, 2016, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells

Huan Wang, Hong Sun, Q. Qu, 2016, PloS one.

Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

Hong Sun, Hui Chen, Huan Wang, 2011, Evidence-based complementary and alternative medicine : eCAM.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

E. Sellers, J. Wagner, J. McCrea, 2016, Journal of clinical psychopharmacology.

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

S. Silberstein, R. Cady, D. Dodick, 2016, The Lancet Neurology.

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

E. Vuurman, A. Vermeeren, S. Jongen, 2016, Psychopharmacology.

Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events

H. Chen, Min Chen, Hong Sun, 2022, Journal of cardiovascular pharmacology.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.

C. Lines, M. Kryger, J. Wagner, 2015, Respiratory medicine.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects

C. Lines, G. Zammit, J. Wagner, 2015, Journal of clinical pharmacology.

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

C. V. Van Leeuwen, E. Vuurman, A. Vermeeren, 2015, Sleep.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

C. Lines, J. Chodakewitz, Junshui Ma, 2013, Sleep.

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

T. Marbury, D. Panebianco, M. Murphy, 2009, Anesthesia and analgesia.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects

J. Wagner, K. Yee, J. McCrea, 2015, Journal of psychopharmacology.

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

E. Vuurman, A. Vermeeren, S. Jongen, 2016, Psychopharmacology.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.